Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

Microscopic view of stem cells with pink nuclei for type 1 diabetes research

Chinese researchers reverse type 1 diabetes using a patient’s own stem cells

Type 1 diabetes reversal using a patient’s own stem cells marks a historic milestone in medicine. A 25-year-old woman in China received a transplant of insulin-producing cells reprogrammed from her own body, and within three months was generating insulin naturally — eventually eliminating her need for external injections entirely. Published in Cell in 2024, the research is significant because it bypasses donor tissue and immunosuppressant drugs entirely, dramatically reducing rejection risk. For the roughly 8.4 million people worldwide living with type 1 diabetes, this proof of concept offers a genuinely new direction for treatment.

Anatomical model of human lungs showing internal airways and blood vessels

World’s first mRNA lung cancer vaccine enters human trials in seven countries

A landmark mRNA lung cancer vaccine is now being tested in human patients for the first time, marking a historic milestone in cancer treatment. BNT116, developed by BioNTech, uses the same messenger RNA technology behind COVID-19 vaccines to train the immune system to recognize and destroy non-small cell lung cancer cells. The phase 1 trial spans 34 sites across seven countries, with roughly 130 patients enrolled. Unlike chemotherapy, this approach targets only tumor cells, potentially offering a more precise and lasting defense against the world’s deadliest cancer, which kills 1.8 million people annually.

Fervo Energy geothermal plant

World’s biggest geothermal power purchase agreement completed in western U.S.

A Utah geothermal project just secured what developers are calling the world’s largest geothermal power purchase agreement — a 15-year deal to deliver 320 megawatts of always-on clean electricity to Southern California Edison, enough to power roughly 350,000 homes. Fervo Energy’s Cape Station plant uses horizontal drilling borrowed from the oil and gas industry to circulate water through deep hot rock, unlocking geothermal power in places where it was never viable before. First electrons are expected to flow in 2026, with the rest coming online by 2028. For a clean grid that needs to run when the sun sets and the wind stops, this kind of steady, weather-proof power may be the missing piece — and a signal that geothermal is ready for prime time.

Colorized scanning electron microscope image of HIV particles (yellow) on a human T cell (blue)

New twice-yearly shot to prevent HIV achieves 100% success rate in late-stage trial

Lenacapavir, a twice-yearly HIV prevention shot, protected every single one of 2,134 women who received it in a late-stage trial across South Africa and Uganda — a 100% efficacy result so striking that monitors ended the blinded phase early. The breakthrough matters because daily prevention pills, while powerful in theory, often falter in real life: stigma, forgotten doses, and disrupted routines all chip away at protection. Two clinic visits a year, by contrast, means a full year of coverage. The remaining hurdle is access, with advocates pressing manufacturer Gilead to license generic versions for the regions hardest hit. If that happens, a tool this effective could reshape the global push to end the HIV epidemic by 2030.

X-ray image of the intestine

New bowel cancer drug is found to be 100% effective

Immunotherapy just delivered something almost unheard of in cancer research: every single one of 42 patients in a rectal cancer trial showed no detectable tumour after treatment with the drug dostarlimab. Even more encouraging, the first 24 patients have now been tracked for an average of 26 months, and their cancers haven’t come back. For people with this specific subtype, it could mean skipping the chemotherapy, radiation, and surgery that often leave lasting damage. Larger studies are now underway to confirm the findings, but the signal is remarkable. It’s a glimpse of where cancer care may be heading worldwide — treatments that work with the body’s own immune system, and let patients keep their lives intact.

Holding breast cancer ribbon

New blood test can predict breast cancer return

A new blood test for breast cancer recurrence spotted returning disease an average of 15 months before symptoms or scans — and in one case, a full 41 months ahead of diagnosis. In a UK trial of 78 patients, the test correctly flagged every woman who later relapsed, scanning for 1,800 cancer-related mutations in tiny fragments of tumour DNA left circulating after treatment. Lead researcher Dr. Isaac Garcia-Murillas explained that dormant cells too few to show up on scans can trigger relapse years later — exactly the blind spot this test targets. If larger studies confirm the results, a simple blood draw could give oncologists precious extra time to act, reshaping how recurrence is caught worldwide.

Close-up 3D render of pink spherical cancer cells on dark background

NHS launches world-first cancer vaccine matchmaking program in England

Cancer vaccine trials are now being fast-tracked through a landmark NHS program in England that matches patients with personalized mRNA vaccines built around their individual tumors. The Cancer Vaccine Launch Pad, operating across 30 hospitals, uses the same mRNA technology behind COVID-19 vaccines to design custom treatments targeting each patient’s unique cancer mutations. The program aims to eliminate remaining cancer cells after surgery before they can return. Early immune response data is encouraging, and a 2024 trial showed a 44% reduction in melanoma recurrence when similar vaccines were combined with immunotherapy.

3D illustration of a synapse transmitting neurotransmitters between two neurons

Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

A once-daily ALS pill designed to rebuild neural connections — not just slow their loss — has cleared FDA approval to begin Phase 2 trials, with patients across the U.S. starting doses in April 2024. SPG302 works on synapses, the tiny junctions where neurons talk to each other, which start vanishing before motor neurons themselves die. Every ALS drug currently on the market aims to slow decline; this one is being tested for whether it can actually help recover lost function. For the roughly 30,000 Americans living with ALS, that’s a genuinely different question to be asking. If it works, it could reshape how researchers approach neurodegenerative disease far beyond ALS.

Close-up of a mosquito resting on a green leaf, relevant to malaria prevention

New types of mosquito bed nets could cut malaria risk by up to half, trial finds

New mosquito bed nets cut malaria transmission by 20 to 50 percent in a major trial across 17 African countries, offering a real answer to the growing problem of insecticide resistance. The nets pair the standard pyrethroid coating with a second insecticide that hits mosquitoes through a different biological pathway, so the ones that used to shrug off treated nets no longer can. At under three dollars each, they cost about the same as the older versions they’re replacing. Paired with the malaria vaccine now rolling out across Africa, these nets are part of a layered defense that could meaningfully shift the trajectory of a disease that still kills hundreds of thousands of people every year.

Close-up of blue solar panels reflecting sunlight, used in utility-scale and campus solar installations

Turkish scientists develop “bumpy” solar panel concept that can harvest up to 66% more energy

Dome-shaped solar cells could absorb up to 66% more light than their flat counterparts, according to new simulations from a research team at Abdullah Gül University in Türkiye. The trick is geometric: tiny hemispherical bumps catch sunlight from many angles at once, acting almost like little lenses that funnel light into the cell. That means solar power could finally work well on surfaces that flat panels struggle with, like clothing, curved windows, greenhouse roofs, and wearable medical devices. The design still needs to be built and tested in the real world, but it points toward a future where solar generation lives quietly inside the everyday surfaces around us, rather than only on dedicated rooftops.